Aytu Biopharma, Inc.
AYTU
$2.39
$0.0954.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 111.98% | 70.87% | 74.46% | 7.08% | 55.40% |
| Total Depreciation and Amortization | -17.25% | -21.39% | -19.89% | -19.33% | -18.34% |
| Total Amortization of Deferred Charges | -33.56% | -5.57% | 32.81% | 89.62% | -- |
| Total Other Non-Cash Items | -136.12% | -133.94% | -100.57% | 39.18% | 15.92% |
| Change in Net Operating Assets | -173.38% | 1,657.89% | -301.82% | 8.05% | 80.43% |
| Cash from Operations | -163.07% | -88.99% | -162.16% | 72.94% | 140.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 92.44% | 80.68% | -7.66% | -181.20% | -1,316.22% |
| Cash from Investing | 194.00% | 210.64% | 154.47% | -181.20% | -14,900.00% |
| Total Debt Issued | 426.34% | 527.24% | 467.50% | -- | -199.73% |
| Total Debt Repaid | -627.49% | -448.80% | -487.96% | -570.16% | -812.16% |
| Issuance of Common Stock | 27.63% | -17.29% | -32.80% | -77.74% | -79.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -190.53% | 6.60% | 82.64% | 34.86% | 74.54% |
| Cash from Financing | 145.49% | 95.58% | 132.12% | -114.23% | -158.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -373.15% | 3,003.57% | 103.74% | -182.18% | 106.89% |